On January 13, 2015, CoLucid Pharmaceuticals, Inc., announced that it had completed a $37.1 million Series C preferred stock offering. The financing was led by TVM Capital Life Science, based in Montreal and Munich, and included participation from new investors Novo Ventures and Auriga Partners. CoLucid’s existing investors also participated.

CoLucid is developing oral lasmiditan for the acute treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.

TVM Capital Life Science provides venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with in excess of US$1.3 billion under management.

Gowlings advised TVM with respect to this investment with a team that included Vanessa Grant and Matthew Literovich.